In last trading session, Procept BioRobotics Corp (NASDAQ:PRCT) saw 0.64 million shares changing hands with its beta currently measuring 1.11. Company’s recent per share price level of $57.62 trading at $1.59 or 2.84% at ring of the bell on the day assigns it a market valuation of $3.16B. That closing price of PRCT’s stock is at a discount of -80.16% from its 52-week high price of $103.81 and is indicating a premium of 20.93% from its 52-week low price of $45.56. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.03 million shares which gives us an average trading volume of 891.76K if we extend that period to 3-months.

For Procept BioRobotics Corp (PRCT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.36. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.49 in the current quarter.

Procept BioRobotics Corp (NASDAQ:PRCT) trade information

Upright in the green during last session for gaining 2.84%, in the last five days PRCT remained trading in the red while hitting it’s week-highest on Wednesday, 03/12/25 when the stock touched $57.62 price level, adding 8.39% to its value on the day. Procept BioRobotics Corp’s shares saw a change of -28.44% in year-to-date performance and have moved -2.88% in past 5-day. Procept BioRobotics Corp (NASDAQ:PRCT) showed a performance of -13.00% in past 30-days. Number of shares sold short was 5.08 million shares which calculate 5.52 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 105 to the stock, which implies a rise of 45.12% to its current value. Analysts have been projecting 105 as a low price target for the stock while placing it at a high target of 105. It follows that stock’s current price would drop -82.23% in reaching the projected high whereas dropping to the targeted low would mean a loss of -82.23% for stock’s current value.

Procept BioRobotics Corp (PRCT) estimates and forecasts

This year revenue growth is estimated to rise 43.28% from the last financial year’s standing.

9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 65.4M for the same. And 9 analysts are in estimates of company making revenue of 76.4M in the next quarter. Company posted 44.54M and 53.35M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -12.56% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 13.70% while estimates for its earnings growth in next 5 years are of 37.06%.

Procept BioRobotics Corp (NASDAQ:PRCT)’s Major holders

Insiders are in possession of 4.72% of company’s total shares while institution are holding 94.60 percent of that, with stock having share float percentage of 99.28%. Investors also watch the number of corporate investors in a company very closely, which is 94.60% institutions for Procept BioRobotics Corp that are currently holding shares of the company. FMR LLC is the top institutional holder at PRCT for having 7.29 million shares of worth $445.33 million. And as of 2024-06-30, it was holding 14.1215 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 4.71 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.2375 of outstanding shares, having a total worth of $287.87 million.

On the other hand, Vanguard Total Stock Market Index Fund and Fidelity Growth Company Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.63 shares of worth $94.1 million or 2.98% of the total outstanding shares. The later fund manager was in possession of 1.33 shares on Dec 31, 2024 , making its stake of worth around $76.38 million in the company or a holder of 2.42% of company’s stock.